However, when analyzed together with over 3400 samples and 1417 events, the EFS was significantly in favor of anthracyclines for HER2+ disease (HR = 0.71) compared to HR = 0.89 for HER2− breast cancer (p interaction = 0.0485). The gene discussed is ERBB2; the disease is breast carcinoma.